Pharmaceuticals, Biotechnology and Life Sciences
-Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs- -Ribometrix to receive $20 million in upfront payment…
– Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1…
– Oral presentation of ASPIRO results to include additional efficacy and safety data on all patients in dose Cohort 1…
mRNA-3927 is Moderna’s second rare disease program with an open IND mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944…
mRNA-3927 is Moderna’s second rare disease program with an open IND mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944…
NEW YORK–(BUSINESS WIRE)–A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic…
NEW YORK–(BUSINESS WIRE)–A2A Pharmaceuticals Inc. (A2A), a biotechnology company committed to the advancement of innovative scientific research and new therapeutic…
TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective…
TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective…
Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for cancer…